An Intervention Study for Adults with Moderate Plaque Psoriasis

Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy

Study Purpose

The purpose of this study is to evaluate if the study drug, Risankizumab, is more effective to Apremilast in the treatment of moderate plaque psoriasis. The effectiveness of Risankizumab will be evaluated in subjects who have not been treated with Risankizumab and in subjects who switch from Apremilast to Risankizumab.

Who Can Participate

Participants 18 years and older diagnosed with plaque psoriasis for at least six months and have no prior exposure to Skyrizi or Otezla maybe eligible for this study.